Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth

AI-generated analysis

πŸ“… Gilead Sciences (GILD) is scheduled to report its quarter ended March 2026 on May 7.

πŸ“ˆ Analysts anticipate quarterly earnings of $1.89 per share, representing a 4.4% year-over-year increase.

πŸ’° Expected revenue stands at $6.89 billion, marking a 3.4% growth compared to the prior-year quarter.

πŸ“‰ The consensus EPS estimate has been adjusted downward by 0.33% over the last 30 days.

πŸ” Zacks Investment Research's Earnings ESP model indicates a positive reading of +0.33% for Gilead.

πŸ€– This model compares the Most Accurate Estimate against the consensus to predict potential earnings deviations.

πŸš€ A positive Earnings ESP combined with a Zacks Rank #3 suggests a high probability of beating estimates.

πŸ“Š Historical data shows the company beat EPS consensus three times out of the last four quarters.

πŸ‘£ In the last reported quarter, Gilead delivered a surprise with earnings of $1.86 versus an expectation of $1.83.

⚠️ While an earnings beat increases success odds, other factors can influence stock price movement regardless.

πŸ₯ Gilead operates primarily in the HIV and hepatitis C drug markets as a key pharmaceutical player.

πŸ”­ The upcoming results will be critical for determining the sustainability of near-term stock price changes.

πŸ’‘ Analysts have recently become more bullish on Gilead, raising their Most Accurate Estimate above consensus.

πŸ“‰ A negative Earnings ESP or a low Zacks Rank generally makes predicting an earnings miss more difficult than a beat.

πŸ› οΈ Investors are advised to use the Zacks Earnings ESP Filter before making trading decisions around the report date.

Bullish Signals
  • Gilead Sciences is expected to deliver a year-over-year increase in earnings, with consensus estimates projecting quarterly earnings of $1.89 per share representing a +4.4% growth.
  • Revenue is forecasted at $6.89 billion, which reflects a strong 3.4% increase from the same quarter last year.
  • Analysts are becoming more bullish on the company, as the Most Accurate Estimate has recently increased relative to the consensus estimate.
  • The Zacks Earnings ESP model indicates a positive reading of +0.33%, which is a strong predictor that Gilead will likely beat its earnings consensus.
  • Gilead holds a Zacks Rank of #3 (Hold), and research shows that companies with positive Earnings ESP combined with Rank #1, #2, or #3 produce a positive surprise nearly 70% of the time.
  • The company has a strong track record, having beaten consensus EPS estimates three out of the last four quarters.
Risk Factors
  • The consensus EPS estimate for Gilead has been revised down 0.33% over the last 30 days, reflecting a collective bearish reassessment by analysts ahead of the report.
  • Although Gilead beat estimates three times in the last four quarters, a negative Earnings ESP reading is explicitly stated to not be indicative of an earnings miss, introducing uncertainty regarding future predictive accuracy.
  • The company carries a Zacks Rank of #3 (Hold), which the text notes limits the predictive power of its Earnings ESP model compared to 'Strong Buy' or 'Buy' ratings.
  • Investors are warned that even an earnings beat may not be sufficient to move the stock higher if other business conditions disappoint investors, indicating potential downside catalysts unrelated to earnings numbers.
Full Analysis
Gilead Sciences (GILD) is set to report quarterly earnings for the period ended March 2026, with Wall Street anticipating a year-over-year increase in both revenue and earnings per share. Analysts project quarterly revenues of $6.89 billion, representing a 3.4% increase from the prior year, while estimated EPS stands at $1.89, marking a 4.4% growth. These figures are expected to be released on May 7, with positive results potentially driving the stock higher, though misses could lead to downward pressure on the share price. Ahead of the release, the consensus EPS estimate has seen slight revisions downward by 0.33% over the last 30 days, yet the Zacks Earnings Expected Surprise Prediction (ESP) model indicates a positive reading of +0.33%. This metric compares the most accurate recent estimates against the broader consensus, suggesting that analysts with the latest data have become bullish on Gilead. The company currently holds a Zacks Rank of #3 (Hold), and historically, stocks combining a positive ESP with ranks of 1 through 3 beat earnings expectations roughly 70% of the time. Gilead has a strong track record regarding these projections, having beaten consensus EPS estimates in three out of its last four quarters. For the final reported quarter before this one, the company posted actual earnings of $1.86 per share against an expected $1.83, resulting in a positive surprise of 1.64%. While earnings beats are not the sole driver of stock price movement due to other business factors, Gilead appears to be a compelling candidate for beating consensus estimates based on current analyst sentiment and historical performance, with results likely influencing both immediate stock price action and future earnings expectations during management's discussion.